$BIEL ELECTROMAGNETIC PAIN RELIEF/BLOCKING: FEASIBILITY ASSESSMENT
https://ntrs.nasa.gov/api/citations/202050088...4Sep20.pdf
https://youtu.be/cGSbtEjJWCk
https://ntrs.nasa.gov/api/citations/202050088...4Sep20.pdf
https://youtu.be/cGSbtEjJWCk
Quote:ELECTROMAGNETIC PAIN RELIEF/BLOCKING: FEASIBILITY ASSESSMENT
page 15
The treatment method ranked first in this review was pulsed
shortwave therapy (PSWT), a low-power RF (MHz range)
transmitter operated adjacent to biological tissue at maximum
output (saturation) to modulate peripheral nerve activity.
ActiPatch is a very small wearable PSWT device that is FDA
approved for “adjunctive treatment of musculoskeletal pain”
[Anwar-Deen 2020]. It is low cost, low power, and boasts 97%
efficacy in reducing pain (85% over a 6-month period) [Staelin
2019]. The device can be secured to the body by physio tape and
the area causing pain is bounded by the device’s ring. The device
can be turned on and off, and the non-rechargeable battery is capable of 720 hours of operation
(one month continuous use). ActiPatch is sold OTC in local pharmacies for ~$30 [ActiPatch
2020].
